News Conference News ACC 2017 CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS Yael L. Maxwell March 18, 2017
News Conference News ACC 2017 ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s Yael L. Maxwell March 17, 2017
News Conference News ACC 2017 People Living in Amazon Rainforest Provide Clues to Coronary Protection L.A. McKeown March 17, 2017
News Conference News ACC 2017 SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab Yael L. Maxwell March 17, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2017 Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term Michael O'Riordan March 10, 2017
News Conference News ACC 2017 Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions Shelley Wood March 09, 2017
News Conference News ACC 2017 More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease Yael L. Maxwell March 09, 2017
News Conference News ACC 2016 STEPATHLON: A Mobile-Based Exercise Program Increased Physical Activity and Promoted Weight Loss Michael O'Riordan April 04, 2016
News Conference News ACC 2016 Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH Michael O'Riordan April 03, 2016
News Conference News ACC 2016 HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not Michael O'Riordan April 02, 2016